The effect of anastomotic leakage on the incidence of recurrence after tri‐modality therapy for esophageal adenocarcinomas
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Wessel T Stam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Surgery, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant chemoradiotherapy (nCRTx) reduces the incidence of recurrence, while anastomotic leakage has shown increase the risk of recurrence. The primary objective of this retrospective study was to investigate the incidence and pattern of recurrence and secondary median recurrence‐free interval and post‐recurrence survival in patients with and without anastomotic leakage after multimodal therapy for esophageal adenocarcinoma.
Methods
Patients with recurrence after multimodal therapy between 2010 and 2018 were included.
Results
Six hundred and eighteen patients were included, 91 (14.7%) had leakage and 278 (45.0%) recurrence. Patients with leakage did not develop recurrence more often (48.4%) than those without (44.4%, [ p = 0.484]). Recurrence‐free interval for patients with ( n = 44) and without leakage ( n = 234) was 39 and 52 weeks, respectively ( p = 0.049). Post‐recurrence survival was 11 and 16 weeks, respectively ( p = 0.702). Specified by recurrence site, post‐recurrence survival for loco‐regional recurrences was 27 versus 33 weeks ( p = 0.387) for patients with and without leakage, for distant 9 versus 13 ( p = 0.999), and for combined 11 versus 18 weeks ( p = 0.492). Conclusion and Discussion No higher incidence of recurrent disease was observed in patients with anastomotic leakage, however it is associated with a shorter recurrence‐free interval. This could have implications for surveillance, as early detection of recurrent disease could influence therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amsterdam UMC location Vrije Universiteit Amsterdam, Surgery, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Surgery, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Radiotherapy, Amsterdam, The Netherlands.
- Amsterdam UMC location University of Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands.
Zitieren
APA
Stam, W. T., Schuring, N., Hulshof, M., van Laarhoven, H., Derks, S., van Berge Henegouwen, M. I., van der Peet, D. L., Gisbertz, S. S., & Daams, F. (2023). The effect of anastomotic leakage on the incidence of recurrence after tri‐modality therapy for esophageal adenocarcinomas. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27293
Vancouver
Stam WT, Schuring N, Hulshof M, van Laarhoven H, Derks S, van Berge Henegouwen MI, et al. The effect of anastomotic leakage on the incidence of recurrence after tri‐modality therapy for esophageal adenocarcinomas. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27293
BibTeX
@article{Stam2023,
author = {Stam, Wessel T and Schuring, Nannet and Hulshof, Maarten and van Laarhoven, Hanneke and Derks, Sarah and van Berge Henegouwen, Mark I and van der Peet, Donald L and Gisbertz, Suzanne S and Daams, Freek},
title = {The effect of anastomotic leakage on the incidence of recurrence after tri‐modality therapy for esophageal adenocarcinomas},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27293}
}
EUVIMED